Company Overview
Inspira Technologies Oxy B.H.N. Ltd. operates within the healthcare sector, specifically focusing on the medical devices industry where it specializes in proprietary life support technologies designed for the treatment of acute respiratory failure in Israel. The company engages in the comprehensive process of research, development, manufacturing, and marketing of its core offerings, which include the INSPIRA ART100 life support system utilized in prosthetic applications. As of the latest reporting period, the company holds a market capitalization of $17.01M and reported annual revenue of $289,000. The absence of available employee count data suggests a specific operational structure or reporting limitation regarding workforce size for this specialized entity. The market capitalization figure of $17.01M, when juxtaposed against the revenue of $289,000, indicates a significant valuation premium relative to current sales output, which is characteristic of early-stage medical device firms where future growth potential and intellectual property value often outweigh immediate revenue generation.
Financial Health
The company reported a revenue of $289,000 over the trailing twelve months, while simultaneously reporting a net income of $-13,220,000 and an EBITDA of $-13,473,000. The substantial gap between the modest revenue figure and the massive net loss reveals a highly leveraged cost structure where expenses, likely including significant R&D and manufacturing costs for proprietary devices, far exceed current sales revenue. Free cash flow stands at $-9,243,375, indicating a heavy cash burn rate that limits the company's financial flexibility and necessitates external capital raising or existing cash reserves to sustain operations. The gross margin is recorded at 0.7%, which suggests that the cost of goods sold consumes nearly the entirety of revenue before operating expenses are considered. The operating margin is listed at -4713.8%, a figure that reflects the intense operational leverage and high fixed cost environment typical of medical device development, while the profit margin sits at 0.0%. On the liquidity front, the company holds $3.16M in cash against $480,000 in debt, resulting in a debt-to-equity ratio of 20.66. Despite the low absolute debt amount, the high debt-to-equity ratio indicates a leveraged balance sheet rather than a conservative one, as equity is likely very small relative to debt obligations. The current ratio is 1.56, which indicates that the company possesses sufficient current assets to cover its short-term liabilities, providing a buffer against immediate liquidity pressures. Return on equity is -397.9% and return on assets is -127.0%, metrics that reveal management is currently unable to generate positive returns on the capital invested by shareholders or utilized in assets due to the prevailing losses.
Valuation Assessment
The trailing twelve-month P/E ratio is not available due to negative earnings, whereas the forward P/E is reported at -0.56. The negative forward P/E implies that the market expects earnings to remain negative in the near term, preventing a traditional multiple calculation based on expected positive profitability. The price-to-book ratio stands at 6.05, indicating that the market values the company at a significant premium over its book value, which often occurs when investors price in future growth potential or the value of intangible assets like intellectual property. The price-to-sales ratio is 58.86, a metric that suggests the market is willing to pay a very high multiple relative to revenue, typical for biotech or medical device companies in development phases. The EV/EBITDA ratio is -0.85, further reinforcing the lack of current earnings power. Regarding trading range, the 52-week high is $1.65 and the 52-week low is $0.34. Without a specific current share price provided in the source data to calculate the exact percentage, the stock trades within this established volatility range defined by these extremes. The beta value is not available, meaning there is insufficient data to quantify the stock's price volatility relative to the broader market movements during this period.
Growth & Income
The revenue growth year-over-year is not available, and earnings growth year-over-year is also not available, preventing a direct comparison of earnings growth speed relative to revenue. The inability to calculate growth rates suggests either a lack of historical data or a fundamental shift in the business model that obscures year-over-year comparisons. The company does not pay dividends, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%. Consequently, the company does not distribute earnings to shareholders but instead retains all capital, which is typically reinvested into research, development, and manufacturing capabilities to attempt future growth. The overall growth and income profile is characterized by a lack of current profitability and no dividend income, relying entirely on the potential for future market expansion and product adoption in the respiratory failure treatment sector.